Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 Studies.

Autor: Ten Bokkel Huinink S; Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands., Thomassen D; Leiden UMC, Department of Biomedical Data Sciences, Leiden, The Netherlands., Steyerberg EW; Leiden UMC, Department of Biomedical Data Sciences, Leiden, The Netherlands.; Erasmus MC, Department of Public Health, Rotterdam, The Netherlands., Pauwels RWM; Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands., Casanova MJ; Hospital Universitario de La Princesa, Department of Gastroenterology, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid (UAM) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain., Bouguen G; University Hospital of Pontchaillou, Department of Gastroenterology and Hepatology, Rennes, France., Mak JWY; Chinese University of Hong Kong, Department of Medicine and Therapeutics, Hong Kong, Hong Kong., Molnár T; University of Szeged, First Department of Medicine, Szeged, Hungary., Lobo AJ; Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Department of Gastroenterology and Hepatology, Sheffield, UK., Seidelin JB; Herlev Hospital, Department of Gastroenterology, University of Copenhagen, Denmark., Amiot A; Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris Est Creteil University (UPEC), Department of Gastroenterology, Creteil, France., D'Haens G; Amsterdam UMC, Academic Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands., Rivière P; Hospitalier Universitaire, Department of Gastroenterology and Hepatology, Bordeaux, France., Guidi L; Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Department of Gastroenterology, Rome, Italy., Bor R; University of Szeged, First Department of Medicine, Szeged, Hungary., Lin WC; Mackay Memorial Hospital, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei, Taiwan., Peyrin-Biroulet L; University Hospital of Nancy, Department of Hepato-Gastroenterology, Vandoeuvre-les-Nancy, France., Gisbert JP; Hospital Universitario de La Princesa, Department of Gastroenterology, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid (UAM) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain., Janneke van der Woude C; Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands., de Vries AC; Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands.

Publikováno v: Journal of Crohn's & colitis [J Crohns Colitis] 2024 Jan 27; Vol. 18 (1), pp. 134-143.

Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction.

Autor: Proietti E; Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, the Netherlands.; Department of Medicine and Surgery, University of Perugia, Perugia, Italy., Pauwels RWM; Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, the Netherlands., van der Woude CJ; Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, the Netherlands., Doukas M; Department of Pathology, Erasmus Medical Center, Rotterdam, the Netherlands., Oudijk L; Department of Pathology, Erasmus Medical Center, Rotterdam, the Netherlands., Peppelenbosch MP; Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, the Netherlands., Grohmann U; Department of Medicine and Surgery, University of Perugia, Perugia, Italy., Crombag MBS; Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, the Netherlands., de Vries AC; Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, the Netherlands., Fuhler GM; Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, the Netherlands.

Publikováno v: Inflammatory bowel diseases [Inflamm Bowel Dis] 2023 Jul 05; Vol. 29 (7), pp. 1038-1046.

Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.

Autor: van Linschoten RCA; Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, Netherlands; Department of Gastroenterology and Hepatology, Franciscus Gasthuis and Vlietland, Rotterdam, Netherlands., Jansen FM; Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, Netherlands., Pauwels RWM; Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, Netherlands., Smits LJT; Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, Netherlands., Atsma F; Radboud Institute for Health Sciences, Scientific Center for Quality of Healthcare, Radboud University Medical Center, Nijmegen, Netherlands., Kievit W; Radboud institute for Health Science, Department for Health Evidence, Radboud University Medical Center, Nijmegen, Netherlands., de Jong DJ; Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, Netherlands., de Vries AC; Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, Netherlands., Boekema PJ; Department of Gastroenterology and Hepatology, Maxima Medical Center, Eindhoven, Netherlands., West RL; Department of Gastroenterology and Hepatology, Franciscus Gasthuis and Vlietland, Rotterdam, Netherlands., Bodelier AGL; Department of Gastroenterology and Hepatology, Amphia Hospital, Breda, Netherlands., Gisbertz IAM; Department of Gastroenterology and Hepatology, Bernhoven Hospital, Uden, Netherlands., Wolfhagen FHJ; Department of Gastroenterology and Hepatology, Albert Schweitzer Hospital, Dordrecht, Netherlands., Römkens TEH; Department of Gastroenterology and Hepatology, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands., Lutgens MWMD; Department of Gastroenterology and Hepatology, Elisabeth Twee Steden Ziekenhuis, Tilburg, Netherlands., van Bodegraven AA; Department of Gastroenterology, Geriatrics, Internal and Intensive Care Medicine (Co-MIK), Zuyderland Medical Center, Sittard-Geleen/Heerlen, Netherlands., Oldenburg B; Department of Gastroenterology and Hepatology, UMC Utrecht, Utrecht, Netherlands., Pierik MJ; Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, Netherlands., Russel MGVM; Department of Gastroenterology and Hepatology, Medisch Spectrum Twente, Twente, Netherlands., de Boer NK; Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, Amsterdam, Netherlands., Mallant-Hent RC; Department of Gastroenterology and Hepatology, Flevoziekenhuis, Almere, Netherlands., Ter Borg PCJ; Department of Gastroenterology and Hepatology, Ikazia Hospital, Rotterdam, Netherlands., van der Meulen-de Jong AE; Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, Netherlands., Jansen JM; Department of Gastroenterology and Hepatology, OLVG, Amsterdam, Netherlands., Jansen SV; Department of Gastroenterology and Hepatology, Reinier de Graaf Gasthuis, Delft, Netherlands., Tan ACITL; Department of Gastroenterology and Hepatology, CWZ Hospital, Nijmegen, Netherlands., van der Woude CJ; Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, Netherlands., Hoentjen F; Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, Netherlands; Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB, Canada. Electronic address: hoentjen@ualberta.ca.

Publikováno v: The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2023 Apr; Vol. 8 (4), pp. 343-355. Date of Electronic Publication: 2023 Jan 31.

Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies.

Autor: Pauwels RWM; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands., van der Woude CJ; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands., Nieboer D; Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands., Steyerberg EW; Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands., Casanova MJ; Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa, Universidad Autónoma de Madrid, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain., Gisbert JP; Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa, Universidad Autónoma de Madrid, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain., Kennedy NA; Exeter Inflammatory Bowel Disease Research Group, University of Exeter, Exeter, United Kingdom; Department of Gastroenterology and Hepatology, Western General Hospital, Edinburgh, United Kingdom., Lees CW; Department of Gastroenterology and Hepatology, Western General Hospital, Edinburgh, United Kingdom., Louis E; Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Liège, Liège, Belgium., Molnár T; First Department of Medicine, University of Szeged, Szeged, Hungary., Szántó K; First Department of Medicine, University of Szeged, Szeged, Hungary., Leo E; Department of Digestive Diseases, Hospital Universitario Virgen del Rocío, Seville, Spain., Bots S; Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Academic Medical Centre, Amsterdam, The Netherlands., Downey R; Department of Gastroenterology and Hepatology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals, National Health Service Foundation Trust, Sheffield, United Kingdom., Lukas M; Inflammatory Bowel Disease Clinical and Research Centre, Iscare a.s, Prague, Czech Republic; Institute of Medical Biochemistry and Laboratory Diagnostics, First Medical Faculty, General Teaching Hospital, Prague, Czech Republic., Lin WC; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan., Amiot A; Department of Gastroenterology, Assistance Publique-Hôpitaux de Paris, Paris Est Creteil University, Henri Mondor Hospital, Paris Est Creteil University; Department of Gastroenterology, Paris Est-Créteil Val de Marne University, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Creteil, France., Lu C; Division of Gastroenterology, Zeidler Ledcor Center, University of Alberta, Edmonton, Alberta, Canada; Division of Gastroenterology, Calgary, Alberta, Canada., Roblin X; Department of Gastro-Enterology, INSERM CIC 1408, Paris, France; Department of Gastroenterology, University of Saint Etienne, Centre Hospitalier Universitaire Hopital Nord, Saint Etienne, France., Farkas K; First Department of Medicine, University of Szeged, Szeged, Hungary., Seidelin JB; Department of Gastroenterology, Herlev Hospital, Herlev, Denmark., Duijvestein M; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands., D'Haens GR; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands., de Vries AC; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: a.c.devries@erasmusmc.nl.

Publikováno v: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2022 Aug; Vol. 20 (8), pp. 1671-1686.e16. Date of Electronic Publication: 2021 Apr 30.

Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease.

Autor: Pauwels RWM; Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands., van der Woude CJ; Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands., Erler NS; Erasmus MC, Department of Biostatistics, Rotterdam, The Netherlands., de Vries AC; Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands, PO Box 2040, Rotterdam, 3000 CA, The Netherlands.

Publikováno v: Therapeutic advances in gastroenterology [Therap Adv Gastroenterol] 2020 Dec 24; Vol. 13, pp. 1756284820979765. Date of Electronic Publication: 2020 Dec 24 (Print Publication: 2020).